Evaluating TRAF3IP2 Levels in Patients With Acute Heart Attacks
Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction
Nanjing Medical University · NCT06038994
This study is testing if measuring TRAF3IP2 levels in people who have had a heart attack can help predict their risk of serious heart problems later on.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Nanjing Medical University (other) |
| Locations | 1 site (Huai'an, Jiangsu) |
| Trial ID | NCT06038994 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the prognostic value of surem TRAF3IP2 levels in patients diagnosed with acute myocardial infarction who undergo coronary angiography. It will involve measuring TRAF3IP2 levels using ELISA and analyzing their association with major adverse cardiac events (MACEs). The research builds on previous findings in animal models, seeking to provide human data on the role of TRAF3IP2 in heart disease.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with acute myocardial infarction who have undergone coronary angiography.
Not a fit: Patients with advanced heart failure, malignancies, acute infections, or other significant health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify patients at higher risk for adverse cardiac events following a heart attack.
How similar studies have performed: While previous studies have shown the role of TRAF3IP2 in animal models, this approach is novel in human subjects.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with acute myocardial infarction 2. patients received coronary angiography 3. invasive management within 72 h of hospital admission Exclusion Criteria: 1. NYHA III-IV 2. malignant tumor 3. acute infection 4. thyroid dysfunction 5. Life expectancy of b1 y 6. Unsuitable for PCI
Where this trial is running
Huai'an, Jiangsu
- Huai'an First People's Hospital — Huai'an, Jiangsu, China (RECRUITING)
Study contacts
- Principal investigator: Shuren Ma, MD. — NJMU
- Study coordinator: Jin Geng, MD.
- Email: gj885258@163.com
- Phone: +86-17753124846
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Myocardial Infarction, Acute, TRAF3IP2, Myocardial Infarction, Coronary angiography, MACEs